%D8%B1%D8%A7%D8%B3%D8%A7%D8%AC%D9%8A%D9%84%D9%8A%D9%86Category:RasagilineRasagilinRasagilineRasagilinaRasagiliiniRasagiline%D7%A8%D7%A1%D7%92%27%D7%99%D7%9C%D7%99%D7%9FRasagilinaRasagilinumRasagilineRasagilinaRasagilin%C4%83%D0%A0%D0%B0%D0%B7%D0%B0%D0%B3%D0%B8%D0%BB%D0%B8%D0%BDRasagilinRasagilinRasagilin%D0%A0%D0%B0%D0%B7%D0%B0%D0%B3%D1%96%D0%BB%D1%96%D0%BDQ420685%E9%9B%B7%E6%B2%99%E5%90%89%E5%85%B0
about
P2176
Rasagiline in the Treatment of Persistent Negative Symptoms of SchizophreniaRasagiline for Gait TreatmentSafety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's DiseaseRasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD)Effect of Rasagiline on BIA 9-1067 PharmacokineticsEffect of BIA 9-1067 on Rasagiline PharmacokineticsRasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa in ChinaA Double Blind Placebo Controlled Trial Evaluating Rasagiline Effects on Cognition in Parkinson's Disease Patients With Mild Cognitive Impairment Receiving Dopaminergic TherapyEffects of Rasagiline on Sleep Disturbances in Parkinson's DiseaseTrial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS)A Phase 3 Study With P2B001 in Subjects With Early Parkinson'sRasagiline Tablets Special Drug Use-Results Survey "Survey on Long-term Safety"
P4844
Rasagiline-induced delay of retinal ganglion cell death in experimental glaucoma in rats.A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes.The monoamine oxidase type B inhibitor rasagiline in the treatment of Parkinson disease: is tyramine a challenge?Determining the efficacy of rasagiline in reducing bradykinesia among Parkinson's disease patients: a review.Explaining ADAGIO: a critical review of the biological basis for the clinical effects of rasagiline.Neuroprotective profile of the multitarget drug rasagiline in Parkinson's disease.Rasagiline in Parkinson's disease.The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study.Type A monoamine oxidase is associated with induction of neuroprotective Bcl-2 by rasagiline, an inhibitor of type B monoamine oxidase.Effect of rasagiline on the molecular composition of the excitatory postsynaptic density.Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease.Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson's disease.Rasagiline interferes with neurodegeneration in the Prph2/rds mouse.Long-term, open-label, phase 3 study of rasagiline in Japanese patients with early Parkinson's diseaseLong-term safety and efficacy of adjunctive rasagiline in levodopa-treated Japanese patients with Parkinson's diseaseRasagiline: time to onset of antiparkinson effect is similar when used as a monotherapy or adjunct treatmentOutcomes from switching from rotigotine patch to alternate therapies in Parkinson's disease
P921
Q61917897-63730749-85AC-4383-AD27-A11B0D0E683AQ61936321-A154063A-684A-41B7-B1DA-437ED49D82D4Q61975511-70D23550-1AEE-4ACA-9369-DF66EDE8F238Q62105889-ADA1C7FF-274F-40DB-9861-0AC9591AA62CQ63316535-F8CA6598-5395-40CC-82FF-483CB79409C7Q63316539-7636EDE5-9B18-4E3C-ADDD-BAA45945CACCQ63318294-49773306-D9D0-43F4-8DE1-3253C17DF8DDQ63318722-1CB3A5FE-3BB7-4164-8BC8-27462035F9B4Q63322131-3A5E3D00-9E43-47C2-9CC7-A6DEE1637E62Q63340976-A8B3EE4B-9570-4D9D-BC27-86AEF7AD03A2Q63533967-9A90FEAF-BAF7-460B-93E1-12C8F969CB64Q63596988-3355F9A5-BA90-47EC-81A5-9A4F48BF3410
P4844
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Rasagiliini
@fi
Rasagilin
@de
Rasagilin
@sh
Rasagilin
@sr
Rasagilin
@sv
Rasagilina
@es
Rasagiline
@nl
Rasagilinum
@la
rasagilina
@it
rasagilina
@pl
type
label
Rasagiliini
@fi
Rasagilin
@de
Rasagilin
@sh
Rasagilin
@sr
Rasagilin
@sv
Rasagilina
@es
Rasagiline
@nl
Rasagilinum
@la
rasagilina
@it
rasagilina
@pl
altLabel
(1R)-N-Propargylindan-1-amine
@en
(1R)-N-propargylindan-1-amine
@en
(R)-Indan-1-yl-prop-2-ynyl-amine
@en
(R)-N-2-Propynyl-1-indanamine
@en
(R)-indan-1-yl-prop-2-ynyl-amine
@en
136236-51-6
@fr
Azilect
@fi
Azilect®
@en
C12H13N
@fr
RAS
@en
prefLabel
Rasagiliini
@fi
Rasagilin
@de
Rasagilin
@sh
Rasagilin
@sr
Rasagilin
@sv
Rasagilina
@es
Rasagiline
@nl
Rasagilinum
@la
rasagilina
@it
rasagilina
@pl